A New Revolution In Disease Tissue Processing
Obtaining high-resolution information from solid tumors, while maintaining the global perspective needed to understand the complex tumor microenvironment, represents a key challenge for preclinical and clinical cancer applications. Technologies currently utilized for preclinical as well as diagnostic, prognostic, and predictive clinical cancer research and standard of care practice are dependent on 2-dimensional analysis of thin tissue sections (5-10 micron) in the format of formalin fixed paraffin embedded tissue (FFPE). This is primarily due to the limitations of visualizing thick tissues with conventional light microscopy techniques. Other technologies utilizing molecular technologies have advanced the preclinical and clinical cancer field, however they suffer from the ability to correlate key quantitative information while maintaining tumor and the surrounding microenvironment architecture and morphology. Preserving the spatial information at the same time as capturing high resolution quantitative information, could lead to a better understanding of the role and types of cells within the solid tumor microenvironment.
A new revolution in disease tissue processing, based on transformative optical methods for creating and imaging transparent tissue-gel composites, now addresses this challenge. Exclusively licensed to ClearLight, these technologies include landscape-shifting advances called CLARITY, COLM, and a host of supporting and enabling technologies.
The CLARITY Process
CLARITY allows the transformation of intact tissue into a nanoporous, hydrogel-hybridized form that is crosslinked to a three-dimensional network of hydrophilic polymers. This process produces a fully assembled, intact tissue, which is permeable to macromolecules and optically transparent, thus allowing for robust 3-dimensional imaging of subcellular components (DNA, RNA and protein) and heterogeneous cellular interactions within the tumor microenvironment. In the field of neurobiology, this novel platform has demonstrated an unprecedented capability to visualize three-dimensional architecture, connectivity and molecular relationships within neuronal tissues.
ClearLight Diagnostics (ClearLight) is developing a next generation tissue analysis and imaging technology based on:
1) An exclusive license to the foundational concepts underlying transparent tissue transformation technology including CLARITY and related methods (functional targeted brain endoskeletonization).
2) Exclusive license to all CLARITY diagnostics.
3) Exclusive license to COLM (CLARITY Optimized Light Sheet Microscopy).
All of the above technologies were developed in Dr. Karl Deisseroth's laboratory at Stanford University.
4) Broad intellectual property linking the above licenses to cancer diagnostics and treatment.